About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, June 28th, 2013

The QualityStocks
Daily Stock List


Silver Falcon Mining, Inc. (SFMI)

OTCPicks reported earlier on Silver Falcon Mining, Inc. (SFMI), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Founded in 2007, Silver Falcon Mining, Inc. engages in the exploration and development of gold and silver properties in the United States. The Companyis a junior resource production enterprise that has acquired the rights to develop and operate the mines of GoldLand Holdings, Co., on War Eagle Mountain, on the Owyhee Gold Trend of the Silver City Mining District in southern Idaho. Silver Falcon Mining is based in Bradenton, Florida. The Company also has an office in New York City, and a Woodbridge, Ontario office. The Company lists on the OTC Bulletin Board.

Silver Falcon Mining is also 100 percent owner to the historic Sinker Tunnel and the four mill sites that intersect the main vein of the Oro fino/Golden Chariot vein. The Sinker Tunnel will allow access to the mountain year round via maintained roads. It will also allow Silver Falcon Mining to access possible primary ore reserves through underground mining.

The Company has mineral rights to approximately 1,200 acres on War Eagle Mountain in southern Idaho. Their Diamond Creek Mill is at the foot of War Eagle Mountain; it is serviced by 6.2 miles of paved roads from State Highway 78. Initial production on the mountain is scheduled for this 2013 fiscal year, with an estimated 15-20 year life-of-mines. The estimation is that annual yield, at full capacity, will be $ 6.6 million at the price of gold of $1,650.

In March, Silver Falcon Mining reported that their Diamond Creek Mill Facility's "Denver Flotation Circuit" exceeded expectations in operational results. They reported that recovery from the ore processed by the new circuit exceeds 90 percent of all precious metals contained. This circuit can reach maximum efficiency at a rate of 10 tons per hour. They also stated thatreports on the Sinker Tunnel Gold Project revealed that the Company could extract ore bearing materials.

Moreover, in March, Silver Falcon Mining announced that they began once again to deliver Precious Metal Dore bars to the refinery. On March 12, 2013, they added approximately 33 ounces of precious metal to their account at their refiner in Florida. This shipment came from concentrate produced before the startup of the floatation circuit at their production facilities in Murphy, Idaho. The Company, in April, delivered 52 ounces of Precious Metal Bullion Dore to their contract refinery in Florida.

Silver Falcon Mining, Inc. (SFMI), closed Friday's trading session at $0.0071, down 21.11%, on 1,928,364 volume with 38 trades. The average volume for the last 60 days is 2,473,919 and the stock's 52-week low/high is $0.0052/$0.0504.

Greenfield Farms Food, Inc. (GRAS)

OtcWizard, OTCPicks, and Pumps and Dumps reported earlier on Greenfield Farms Food, Inc. (GRAS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Greenfield Farms Food, Inc. isa diversified food company with a focus on wholesale and retail opportunities.The Company is aproducer and marketer of "grassfed" beef supplying a North Carolina based grocer on a very limited basis. The Company has USDA-FSIS approval to market and label their product as "Grassfed Beef". Currently, Greenfield islooking for other business opportunities to both expand their business and seek greater capitalization. Founded in 2008,Greenfield Farms Food lists on the OTC Markets’ OTCQB.
Greenfield has distributed product on a very limited basis to Lowes Foods Stores. Lowes Foods has approximately 100 locations throughout North and South Carolina. Greenfield Farms Food is hopeful that their change in business plan by way of a new licensing program announced in the first quarter of 2013 will allow them to expand their business and enhance their market and brand presence.
The Company,with this program, will transition from their traditional business model of taking cattle from farm to market (eliminating all of the capital and start-up costs required for such operations) by expanding their brand presence with capable cattle producers and marketers. Additionally, Greenfield believes that the trademark licensing concept will allow for faster market penetration with minimal risk and the ability to more easily determineassumed returns.
Greenfield,in Q1 2013, signed their first licensee, Hill Meadow Foods, Inc., in an exclusive agreement until December 31, 2013; at this time it will become non-exclusive. They believe this time will allow them to appropriatelydevelop the parameters of the licensing program and explore other business opportunities.

Earlier this month,Greenfield Farms Food announced the status of their closing with Carmela's Pizzeria.  The Company reports that at this time, the final closing has not yet been finalized and requires additional time. Upon finalization, the closing will complete the acquisition of 100 percent of the equity interests of Carmela's in a newly created wholly-owned operating subsidiary of Greenfield in exchange for shares of Greenfield stock and warrants.

Greenfield Farms Food, Inc. (GRAS), closed Friday’s trading at $0.0005, up 25.00%, on 22,513,200 volume with 32 trades. The average volume for the last 60 days is 31,288,467 and the stock's 52-week low/high is $0.0002/$0.0075.

Marlborough Software Development Holdings, Inc. (MBGH)

Penny Stock Pick Alert, Winning Penny Stock Picks, WePickPennyStocks, RisingPennyStocks, Super Hot Penny Stocks, Super Nova Stock Picks, Penny Stock MoneyTrain, Penny Stock Pick Report, Liquid Tycoon, and Joe Penny Stocks reported today on Marlborough Software Development Holdings, Inc. (MBGH), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Marlborough Software Development Holdings, Inc. is a software development company whose shares trade on the OTCQB. The Company focuses on bringing innovative and proprietary software products to an extensive array of markets. Pageflex is a division of the Company.Pageflex develops award-winning software technologies and applications for marketing and print automation.Marlborough Software Development Holdings has their corporate headquarters in Marlborough, Massachusetts.

The Company’s core software products include mobile browsing technologies and variable data publishing, Web-to-print, and multi-channel communications technologies. Pageflex products enable companies to manage, streamline, and automate their document production processes, communicate more personally with their customers, and control their brand and market messaging. This is while enabling their remote employees, franchises, and consumers to use a self-serve model to order customized communications. Pageflex solutions use the patented Pageflex variable publishing engine and Adobe® InDesign®.

The Company licenses automated marketing communication and print production products through resellers, original equipment manufacturers(OEMs), and strategic partners. They also license directly to Web-to-print providers, print service providers, marketing services companies, advertising agencies, and corporations.

Furthermore, Marlborough has theirMobile Browsing Technologies. Their BOLT provides a consistent, full desktop-style browsing experience on almost any handset. The BOLT mobile browser offers faithful rendering of Web pages and supports streaming video from popular media sharing sites for mobile phones of all types. BOLT is a WebKit-based cloud computing mobile browser. This cloud computing architecture is the key to BOLT's capabilities. Currently, BOLT does not provide significant revenues and the Company does not make major expenditures pertaining to BOLT.

In April 2013,Marlborough Software Development Holdings reported revenue of $2,335,000 for the three months ended December 31, 2012. This represents an increase of $700,000 or 43 percentin comparison to the three months ended September 30, 2012 and an increase of $150,000 or 7 percentversus revenue of $2,185,000 for the three months ended December 31, 2011.

The Company had an operating loss of $700,000 for the quarter ended December 31, 2012. This represents an improvement of $1,796,000 and $1,519,000, respectively, in comparison to the losses reported for the quarters ended December 31, 2011 and September 30, 2012.

Marlborough Software Development Holdings, Inc. (MBGH), closed at $0.11, up 400.00%, on 547,613 volume with 257 trades. The average volume for the last 60 days is 17,530 and the stock's 52-week low/high is $0.005/$0.89.

Lynas Corp. Ltd. (LYSCF)

SmarTrend Newsletters reported this week on Lynas Corp. Ltd. (LYSCF), Wall Street Wolves, The Bull Report did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lynas Corp. Ltd., together with their subsidiaries, engages in the exploration and development of rare earths minerals mainly in Australia and Malaysia. The Company’s strategy is to create a reliable, fully integrated source of Rare Earths from mine through to market. They also are working to become the benchmark for the security of supply and environmental standards in the global Rare Earths industry. Lynas is based in Sydney, Australia.

The foundation of the Company’s strategy is Mount Weld in Western Australia, and a state-of-the-art Rare Earths processing plant, the Lynas Advanced Materials Plant (LAMP), near Kuantan in Pahang, Malaysia.Construction of Phase 1 of the LAMP in Malaysia completed in 2012. The first Rare Earths concentrate arrived from Western Australia in November 2012. Subsequently, the plant has been progressively commissioned and is ramping up production capacity.

In February 2013, Lynas achieved first production of separated Rare Earths products for customers; they started a process of customer product qualification. The Lynas Advanced Materials Plant (LAMP) has now produced the complete family of Rare Earths products. The plant is ramping up towards achieving targeted Phase 1 nominal capacity of 11,000 tonnes per annum REO by the end of this Q2 2013.

Mount Weld is the richest known deposit of Rare Earths in the world. Concerning the Concentration Plant at Mt. Weld,at the end of the first quarter 2013, 15,593 dry tonnes of concentrate containing 5,540 tonnes of REO were bagged ready for export. The Concentration Plant was handed over to the construction contractor at the start of March 2013 for the final tie-ins and commissioning of the Phase 2 circuit.

Lynas announced, in September 2012, an upgrade to the Mount Weld Ore Reserves. The basis of this is on a mining study that re-optimized the pit design using the updated Mineral Resources estimate announced on January 18, 2012. The revised Ore Reserves at the Central Lanthanide Deposit (CLD), applying cut-off grades ranging from 4 to 7 percent (depending on ore type) are estimated at 9.7 million tonnes at an average grade of 11.7 percent REO for a total of 1.14 million tonnes of contained REO.

Lynas Corp. Ltd. (LYSCF), closed Friday’s trading session at $0.36, up 4.35%, on 269,296 volume with 40 trades. The average volume for the last 60 days is 165,385 and the stock's 52-week low/high is $0.33/$1.00.

Cap-Ex Iron Ore Ltd. (CEV.V)

Today we are highlighting Cap-Ex Iron Ore Ltd. (CEV.V), here at the QualityStocks Daily Newsletter.

Headquartered in Vancouver, British Columbia, Cap-Ex Iron Ore Ltd. focuses on the development of their wholly owned Block 103 Iron Ore Project in the Labrador Trough, near the mining town of Schefferville, Québec. Cap-Ex Iron Ore's shares trade on the TSX Venture Exchange. The Company also has an office in St. John's, NL.

Their Block 103 Property is strategically located close to an existing railway that can provide a direct link to a shipping port. It is next to Tata Steel-New Millenium Iron Corp.’s LabMag and KeMag deposits and the Tata-New Millennium oxide deposits to the east. The Block 103 Property consists of 14 contiguous map-staked licenses totaling 831 mineral claims of 20,775 ha.

Cap-Ex Iron Ore's other projects include Redmond - the claim covers 16,800 hectares 10km south of Schefferville. Projects also include Lac Connelly - 56,000 hectares 250km north of Schefferville; Porky Lake - 9,000 hectares of the Sokoman iron formation 50km northeast of Schefferville, and Snelgrove - 15,400 hectares 50km south of Schefferville. 

Last week, the Company announced that they entered into two additional non-exclusive agreements to seek a strategic partner/investor for the Company's Block 103 Project in western Labrador. They entered into an agreement with Intercedent Ltd. Intercedent is a privately owned Canadian firm with offices in Beijing, Hong Kong and Singapore. In addition, Cap-Ex entered into an agreement with Dublin, Ireland based Pridolian Ltd. Pridolian is a boutique natural resources advisory firm.

Yesterday, Cap-Ex Iron Ore announced that they received the results of the Preliminary Economic Assessment (PEA) on the Block 103 Property. The PEA was completed by BBA, Inc. of Montreal, Québec; the PEA is effective as of June 27, 2013.

The Company has a current Inferred iron ore resource of 7.8 billion tonnes at 29 percent total iron (TFe) and 18.4 percent magnetic iron (magFe). The basis of the PEA was on only the first 30 years of production; this will require the processing of only 1.9 billion tonnes at 28.8 percent TFe and 18.6 percent magFe. The basis of the mineral resource estimate is on a cut-off grade (COG) of 10 percent magFe. 

Cap-Ex Iron Ore Ltd. (CEV.V), closed Friday's trading session at $0.10, down 9.09%, on 61,400 volume. The stock's 52-week low/high is $0.07/$0.50.

Aurcana Corp. (AUNFF)

MonsterStocksPicks, Stock Stars, Streetwise Reports, and ShazamStocks reported earlier on Aurcana Corp. (AUNFF), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Trading on the OTCQX International, Aurcana Corp. is a primary silver producing company. They own 100 percent of the Shafter silver mine (Presidio County, S.W. Texas) and 99.9 percent of the La Negra (Queretaro State, Mexico) silver-copper-lead-zinc mine. Aurcana engages in the production and sale of copper, silver, lead, and zinc concentrates. The Company also engages in the exploration, development, and operation of natural resource properties. Aurcana is based in Vancouver, British Columbia. 

The Shafter silver mine has an NI 43-101 silver resource of 24.6 million ounces Measured and Indicated (2,900,000 tons @ 8.48 opt), 22.8 million ounces Inferred (2,167,000 @ 10.52 opt). It has a pre-feasibility completed. Production is forecast at 3.8 million ounces silver recovered once the mine and mill is operating at capacity.Silver was mined in the Shafter region from 1883 until 1942, when the mine was closed. This was not due to the lack of ore, but by the War Act.  

In 2009, La Negra was milling 1,000 tonnes per day; by 2012, the capacity was expanded to 2,500 tonnes per day. In 2013, the expectation is that capacity will be expanded to 3,000 tonnes per day. A new NI 43-101 report was released for La Negra in August of 2012. It identified 115 million ounces of measured and indicated silver underground, changing the mine life to a minimum of 30 years.The La Negra mine was discovered and developed by Industriales Peñoles S.A. de C.V. The mine began production in 1970. It produced until the mine was put on care and maintenance in 2000.

Yesterday, Aurcana announced that they accepted an indicative terms sheet from RK Mine Finance for an unsecured three year loan facility of $50 million and silver Offtake Agreement for the silver produced at the Shafter mine. RK Mine Financeispart of the Red Kite Group, one of the largest metal merchants in the world.The Board of Directors of Aurcana approved the proposed term sheet. The expectation is that closing will occur in July.The proceeds will be used by Aurcana for the expansion of the Company's mines, as well as for working capital purposes.

Aurcana Corp. (AUNFF), closed Friday at $1.3001, up 17.13%, on 146,109 volume with 95 trades. The average volume for the last 60 days is 73,785 and the stock's 52-week low/high is $0.3365/$4.5072.

CirTran Corp. (CIRC)

UltimatePennyStock and OTCPicks reported previously on CirTran Corp. (CIRC), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets’ OTCQB, CirTran Corp. provides complete product development and manufacturing services for a wide array of business sectors. The Company's roots are as a global, full-service contract manufacturer. They operate along with their Racore Technology electronics manufacturing subsidiary. They operate from an ISO 9001:2000-certified facility. CirTran's operations include CirTran-Asia, CirTran Online, and CirTran Beverage. 

The Company has their headquarters inSalt Lake City, Utah.

Their CirTran-Asia subsidiary has principal offices in ShenZhen, China. They manufacture high-volume electronics, fitness equipment, and household products for the multi-billion-dollar direct response industry. Their CirTran Online offers products directly to consumers through major retail web sites. Their CirTran Beverage has partnered with Play Beverages, LLC, to introduce and distribute the Playboy Energy Drink. 

During 2012, CirTran established operations and gained new revenue in Asia. This included China, the Middle East, and Africa, among other areas. Operations continued in the U.S., South America, Europe and Canada. CirTran had beverage distribution operations in more than 20 countries, entering this year.

In May, CirTran filed their Quarterly Report on Form 10-Q for the period ended March 31, 2013. This Report showsan increase in sales and an improvement in profits. The Company reported that the manufacture and worldwide distribution of their Playboy Energy Drink line continued to drive CirTranin the quarter, representing 96 percent of sales.

For the quarter, the Company reported sales of $868,152. This represents a 40 percent jump over the $618,700 reported for the same period a year prior. CirTran had gross profit of $596,143 in comparison to a loss of $140,454 in the first quarter of 2012. They reported a net loss of $432,480. This represents an improvement of 66 percent over the loss of $1,288,096 reported for the first quarter of fiscal 2012.

Furthermore, in May, CirTranannounced that Playboy’s motion to prevent Play Beverages and CirTran Beverage from selling Playboy Energy Drink was denied by Judge Robert W. Gettleman without prejudice. Play Beverages’ motion to stay the federal action in favor of their state lawsuit in Chicago against Playboy was granted.Playboy had filed on February 1, 2013, seeking to enjoin PlayBev and the CirTran companies from using the trademark; the defendants counter filed on March 5, 2013. Following Judge Gettleman’s ruling, a report for status and review has been set for October 17, 2013.

CirTran Corp. (CIRC), closed Friday's trading session at $0.0004, even for the day, on 42,076,749 volume with 30 trades. The average volume for the last 60 days is 20,043,765 and the stock's 52-week low/high is $0.0002/$0.0039.

NeoMedia Technologies, Inc. (NEOM)

Stock Analyzer, MonsterStocksPicks, and Stock Stars reported earlier on NeoMedia Technologies, Inc. (NEOM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NeoMedia Technologies, Inc.is the pioneer in global mobile barcode management solutions. The Company has more than60 patents awarded and pending in the QR code space worldwide.NeoMedia’s current customers include worldwide brands, agencies and handset manufacturers.NeoMedia Technologies has their headquarters in Boulder, Colorado. The Company has officesaround the U.S. and Europe. In addition, NeoMedia has a development office in Wursulen, Germany. The Company’s shares trade on the OTCQB.

NeoMedia Technologies additionally offers a mobile QR & barcode reader called NeoReader®. It is available for download from all app stores. The Company also offers NeoSphere™, an enterprise grade code creation, resolution and management platform. Moreover, NeoMedia has an intellectual property (IP) portfolio available for license.

The Company’s NeoReader® enables seamless barcode scanning from a mobile device.NeoReader® iscurrently installed on more than 35 million devices. It quickly and easily scans 1D and 2D barcodes, including QR, Datamatrix, Aztec, UPC, and more.

In May,NeoMedia Technologies unveiled their self-service 2D barcode solution, QodeScan.QodeScan’s self-service QR code solution is available in Lite, Basic, and Elite subscriptions. The addition of QodeScan to the Company’s barcode management solution portfolio provides businesses with a new alternative to cost-effectively launch their QR campaigns with a secure, dependable and easy to use interface. QodeScan is supported by NeoReader®.

Last week,NeoMedia Technologies announced that the European Patent Office (EPO) overturned on appeal the earlier revocation of their European Patent No. 0832453. This patent, entitled SYSTEM FOR USING ARTICLE OF COMMERCE TO ACCESS REMOTE COMPUTER, corresponds to the Company’s United States Patents Nos. 6,199,048; 5,978,773; 7,383,209; 7,765,126; and 8,131,597.

With the overturning of the revocation, the EP patent continues to provide NeoMedia with patent coverage across Europeequal with these U.S. patents. The EP patent is registered in the UK, Sweden, Austria, France, Italy, Germany and Switzerland.

NeoMedia Technologies, Inc. (NEOM), closed Friday’s session at $0.0006, up 50.00%, on 404,679,767 volume with 103 trades. The average volume for the last 60 days is 50,904,930 and the stock's 52-week low/high is $0.0001/$0.02.


The QualityStocks
Company Corner


VistaGen Therapeutics, Inc. (VSTA)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.60, even for the day, on 500 volume with 1 trades. The stock’s average daily volume over the past 60 days is 2,730, and its 52-week low/high is $0.06/$1.52.

VistaGen Therapeutics Inc. announced an update on the status of its strategic financing agreement today with Autilion AG, which has committed to invest $36M as per the terms of the amended April 2013 agreement, in consideration for 72m restricted shares of common stock, at a price of $0.50 per share. The first of a series of closings, to be completed on or before September 30, 2013, has already been completed and both parties are excited about the potential this transformative financing will have for the company's pluripotent stem cell technology aimed at drug rescue, predictive toxicology, and drug metabolism assays.

VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.  According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months.  VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits.  In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations. 

AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data.  To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Provides Update on $36 Million Strategic Financing Agreement

VistaGen Therapeutics Presents CardioSafe 3D™ and LiverSafe 3D™ Developments at International Society of Stem Cell Research's 11th Annual Meeting

VistaGen Therapeutics and Duke University Publish Results on Production of Functional 3D Human Heart Tissue


The QualityStocks Daily Newsletter would like to spotlight GRILLiT, Inc. (GRLT). Today, GRILLiT, Inc. closed trading at $0.35, on 650 volume with 2 trades. The stock’s average daily volume over the past 60 days is 6,047, and its 52-week low/high is $0.11/$1.50.

GRILLiT, Inc. announced today that they will be postponing the record date for their previously announced common stock dividend till July 15, 2013 and is issuing notice as per FINRA requirements for market transparency. All shareholders of GRLT owning common shares on the record date of July 15, 2013 shall receive 4 shares of GRILLiT, Inc. common stock for every share held with the dividended common shares being "restricted" as defined in the Securities Act of 1933.

GRILLiT, Inc. (GRLT) was founded on the concept of delivering a fast-casual dining experience with fresh, nutritious home-style cooking. Leveraging more than four decades of experience in the food industry, the founders of GRILLiT established this unique business model to satisfy the ever-increasing demand for delicious and healthy food while providing the perfect ambiance for guest to relax and enjoy great cuisine.

The company sources its ingredients from local and domestic farmers to ensure crisp, fresh produce and grain-fed Angus beef. The cooking techniques and low-sodium recipes employed result in uniquely healthy and delectable meal choices. Using the best possible ingredients, GRILLiT chefs have created an inspiring flavor profile using fresh herbs spices and all-natural marinades.

The management team executing GRILLiT’s business strategy has been carefully assembled to achieve rapid growth and profitability. One of the most recent additions, Rob Elliott, brings more than 25 years of experience in restaurant franchise system development, marketing, branding, and operations. Previously serving as Vice President of Marketing for Little Caesars Pizza, he was instrumental in expanding the number of store locations from 150 to 5,000.

GRILLiT is focused on expanding throughout the southeastern United States and offers nationwide franchising opportunities. Current locations operate in high-traffic shopping plazas and offer American, Asian Fusion, and Latin American food styles. The company’s growth strategy is based on a five-year plan to roll out a total of 79 stores in nine States: Florida, Kentucky, Ohio, New Jersey, New Hampshire, North Carolina, Tennessee, Georgia, and Pennsylvania. Disclaimer

GRILLiT, Inc. Company Blog

GRILLiT, Inc. News:

GRILLiT® Postpones Record Date for Common Stock Dividend

GRILLiT® Brings Top Franchise Branding/PR Firm Aboard

GRILLiT®, Inc. Announces Common Stock Dividend to its Shareholders

StreamTrack, Inc. (STTK)

The QualityStocks Daily Newsletter would like to spotlight StreamTrack, Inc. (STTK). Today, The Aristocrat Group Corp. closed trading at $0.07, on 366,734 volume with 66 trades. The stock’s average daily volume over the past 60 days is 4,837, and its 52-week low/high is $0.11/$4.80.

StreamTrack, Inc. reported a major step forward in its technology Platform for internet broadcasters today as the announcement is made of a new, upgraded release of their UniversalPlayer™, complete with performance optimizations, display, and functional improvements to support the scalability of up to 250k concurrent listeners, becoming available. Faster load time, CDN support, improved caching optimization, and a smaller footprint with smoother execution all combine to offer stations a highly customizable and full-feature environment.

StreamTrack, Inc. (STTK), a digital media and technology services company, provides audio and video streaming and advertising services through its RadioLoyalty™ Platform to a global group of internet and terrestrial radio stations, internet radio guides, and other broadcast content providers. The company's platform powers a web-based and mobile player that manages streaming audio and video content, social media engagement, and ad serving.

StreamTrack offers its platform directly to broadcasters and integrates or white labels its technologies with web-based internet radio guides and other web-based content providers. With StreamTrack technology, broadcasters and publishers are able to maximize their revenue while decreasing expenses, while advertisers are provided with a cost-effective means to reach their target audience from one source at scale.

WatchThis™, StreamTrack's patent-pending technology designed to provide web, mobile, and IP television streaming services that are e-commerce enabled within streamed content, could revolutionize the entertainment industry by combining original network content with interactive product placement. Recognizing the convergence of traditional televised advertisement and internet technology, StreamTrack is advancing its WatchThis™ technology to lead the revolution taking place.

StreamTrack is dedicated to continually creating and managing innovative technology products to provide broadcasters and content owners the most advanced solutions available in the marketplace. Fully committed to also increasing and protecting shareholder value, the management team carefully executes operational, development, and marketing programs with the primary aim of maximizing the company's growth potential and profitability. Disclaimer

StreamTrack, Inc. Company Blog

StreamTrack, Inc. News:

StreamTrack's RadioLoyalty Announces the Release of Its New UniversalPlayer™

StreamTrack's RadioLoyalty Platform™ Adds Over 3,000 Stations

StreamTrack and One World Media Group Announce Agreement With Monaco Media International

Frozen Food Gift Group Inc. (FROZ)

The QualityStocks Daily Newsletter would like to spotlight Frozen Food Gift Group Inc. (FROZ). Today, Frozen Food Gift Group Inc. closed trading at $0.0045, up 80.00%, on 12,000 volume with 1 trades. The stock’s average daily volume over the past 60 days is 162,234, and its 52-week low/high is $0.001/$0.045.

Frozen Food Gift Group Inc. (FROZ) wholly owned subsidiary is named Miami Ice Machine.

In February 2013, Frozen Food Gift Group announced that it had purchased Miami Ice Machine Company (www.MiamiIceMachine.com) for restricted stock. Founded in 1961, Miami Ice Machine (MIMCO) is a leading provider of quality refrigeration equipment of numerous different types, including walk-in refrigerators and state-of-the-art freezers, with more than 50 years of operation. Boasting clientele ranging from nationally franchised businesses to single-location operators, the company is known for its continual innovation and leading refrigeration technologies.

Miami Ice Machine has manufactured and installed more than 100,000 pieces of equipment for its customers in a variety of industries. MIMCO recently announced a long term agreement with BioZone Scientific International to incorporate the latest-generation ice machine sanitation technologies into its complete line of ice machines. This new technology both prevents contamination by harmful bacteria and provides operators a safe and effective way to automate ice machine sanitation. BioZone Scientific’s compact device, IceZone® X, will be included as a standard feature in all new Miami Ice Machine Company machines, the very first time automated ice machine sanitation is included as a standard feature. IceZone® X dramatically reduces the ice machine cleaning cycle by approximately 75 percent, dropping significantly the maintenance burden for operators.

With a solid business model in place, a successful marketing strategy, and direct access to the best refrigeration technologies, the company is well prepared for its future. Disclaimer

Frozen Food Gift Group Inc. Blog

Frozen Food Gift Group Inc. News:

Frozen Food Gift Group Inc. Announces Partnership To Launch Groundbreaking Ice Machine Sanitation Technology

Frozen Food Gift Group Inc. Purchases Ice Machine Firm

VistaGen Therapeutics, Inc. (VSTA) Issues Update on $36M Strategic Financing Agreement with Autlion

VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, recently delivered an overview of key developments involving its CardioSafe 3D™ and LiverSafe 3D™ bioassay systems in poster presentations at the 11th Annual Meeting of the International Society of Stem Cell Research (ISSCR), the largest forum for stem cell and regenerative medicine professionals from around the world, held last week in Boston, Massachusetts.

Dr. Hai-Qing Xian, Senior Scientist, presented VistaGen’s poster entitled “Cardiotoxicity Assessment of Anti-Cancer Kinase Inhibitors using Human Pluripotent Stem Cell-Derived Cardiomyocyte Based Assays,” which detailed important developments demonstrating that CardioSafe 3D™, VistaGen’s high throughput, human heart cell-based bioassay, is a clinically predictive system for preclinical cardiac safety screening of anti-cancer drug candidates, including small molecule kinase inhibitors (KIs), a new category of drugs that have revolutionized cancer therapy due to decreased systemic toxicity and increased target cell efficacy compared to classic cancer drugs, as well as other therapeutic compounds. VistaGen also demonstrated the utility of CardioSafe 3D™ to detect cardiac toxicities of well-known anti-cancer KIs, including imatinib, dasatinib, sunitinib, erlotinib, and temsirolimus, which have been associated with adverse clinical cardiac events that were not detected during the drug development process. As demonstrated in the poster presentation, CardioSafe 3D™ successfully detected cardiotoxicity induced by representative compounds from different KI categories. Additionally, the bioassay system provided clues to the major mechanisms of cardiac cytotoxicity induced by each compound, thus enabling not only the identification of toxicities early in the drug development process, but also discovery of potential mechanisms of action.

Dr. Kristina Bonham, Senior Scientist, Hepatocyte Biology Project Leader, presented VistaGen’s poster entitled “Semi–quantitative assay of CYP3A4 allows the identification and selection of mature human stem cell derived hepatocytes,” which detailed developments indicating that LiverSafe 3D™, VistaGen’s human liver cell-based bioassay, can monitor the induction of the key metabolic enzyme, CYP3A4, and its expression level over time. Using an optimized protocol for the differentiation of hepatocyte-like cells, VistaGen demonstrated levels of CYP3A4 mRNA approaching that in human adult liver on a per cell basis. The reported data suggest that VistaGen’s liver cells have many of the functional properties of mature adult liver cells, enabling multiple functional analyses and providing a powerful system to evaluate the effects of drug candidates on CYP3A4 expression and liver function, offering a valuable aid for assessing potential drug candidates for toxicity and adverse drug-drug interactions.

H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer, emphasized, “For the first time, our technology has caught up with the dreams and visions we had 15 years ago when we founded VistaGen. We now have the type and quality of human cell-based biological assay systems that provide real insight into both the therapeutic and toxic effects of new drug candidates long before they are ever tested in humans. Next-generation biological assays can now provide important preclinical human data that will increase the probability of selecting safer and effective therapeutics for clinical development.”

“It is evident from the mood, tone and scientific discussions throughout the ISSCR conference that this is the most exciting time in the history of stem cell research,” added Dr. Snodgrass. “We anticipate that we will see an explosion over the next ten years in the contribution of human pluripotent stem cell-based biological assays to drug development, in parallel with phenomenal advancements in the therapeutic uses of mature cells and tissues derived from human pluripotent stem cells to treat some of the most intractable human diseases and conditions. Our team is truly fortunate and excited about being a part of this transformational process.”

For more information, visit www.vistagen.com

GRILLiT, Inc. (GRLT) Sets New Record Date for Dividend

GRILLiT, operator of healthy, fast-casual restaurants offering American, Asian Fusion, and Latin American food styles, today told investors that it is postponing the record date for its previously announced common stock dividend. Instead of June 28, 2013, the record date for the stock dividend will be July 15, 2013.

All shareholders of GRILLiT owning common shares on the record date of July 15, 2013, will receive four shares of GRILLiT common stock for every share held by such shareholder. The dividended common shares will be “restricted” as defined in the Securities Act of 1933. Rule 144 allows for the public resale of restricted securities only if certain holding period and other conditions are satisfied.

Per FINRA regulations, the company is required to provide notice to and receive acceptance from FINRA prior to the actual distribution of the dividend. As long as FINRA does not cause any unforeseen delays, GRILLiT anticipates distributing the stock dividend within three to four weeks. The payment of the dividend will not require an increase in the total number of authorized shares of common stock nor is there a need for an exchange of certificates.

For more information, visit www.GRILLiTinc.com

StreamTrack, Inc. (STTK) Unveils New UniversalPlayer with Capacity Upgrade

StreamTrack today announced the release of its upgraded UniversalPlayer™. The new platform represents a major step forward in its technology. This advancement includes performance optimizations, display improvements, and functional upgrades to support the scalability of up to 250,000 concurrent listeners.

Performance optimizations include faster loading time, CDN support, improved caching optimization, and a smaller footprint with smoother execution. Furthermore, stations can now pick between 11 different new themes to customize the look and feel of their player. Functionally, new stream formats supported now include: AAC, AAC+, RTMP, HDS, and HLS. Improvements to optimize flash functionality were also implemented.

StreamTrack CEO Michael Hill stated, “I am very proud of our team for developing such a powerful and innovative product. We have been working on this UniversalPlayer™ for over 6 months, and to see the finished product work so efficiently is a great accomplishment. We are continually trying to improve our Platform and this release demonstrates this. To support our projected increase in listeners, completing this UniversalPlayer™ was required.”

“We are now ready to go to scale with our proven business model: decreasing expense for broadcasters while increasing revenue for everyone in the supply and demand chain,” added Hill. “With the new UniversalPlayer™ being deployed at scale along with our patent-pending instream video ad insertion model, the future looks bright.”

For more information, visit www.streamtrack.com

VentriPoint Diagnostics Ltd. (VPTDF) Offers Superior Solution to Right Heart Analysis

VentriPoint Diagnostics is a Seattle-based provider of a superior heart analysis system. The VentriPoint technology uses conventional 2-dimensional ultrasound data, plus a patented system for analyzing the data called Knowledge-Based Reconstruction (KBR). The result is a 3-dimensional model of the heart, providing critical information regarding things like heart volumes and cardiac output.

The VentriPoint system, called Angelo, is of special value for doing what is called right-heart analysis, where the physician needs a clear view of the portion of the heart that pumps blood to the lungs for oxygenation. It is normally difficult to image the right heart using ultrasound, due to the obstruction of the ribs. As a result, physicians often use MRI imaging to get the necessary detail, even though MRI imaging costs more and is more difficult for the patient, especially for children. The VentriPoint system provides the needed heart information without requiring an MRI, but rather with easy-to-use and far less expensive ultrasound technology. It removes the need to sedate children and for second visits.

The VentriPoint system has key applications for congenital heart disease and pulmonary arterial hypertension, and is being researched for a number of other applications:

• Single ventricle
• Perimount (R) Valves
• Ebsteins
• Workflow analysis
• Economic analysis
• RV to PA conduit
• Left ventricle
• Heart failure
• Coronary artery disease

The system has already been installed in major cardiac centers in Canada, Europe, and North America, and has also been the subject of scientific publications in major heart journals.

For more information, visit www.ventripoint.com


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251